INTRODUCTION
KRAS is a small G protein that acts as a transducer in the epidermal growth factor receptor (EGFR) pathway. Acquired KRAS codon 12 or 13 gain-offunction mutations lead to constitutive signaling through the EGFR pathway and to downstream activation of MAPK-and PI3K-dependent pathways. 1, 2 In approximately 40% of all metastatic colorectal cancer (mCRC) tumors, one of several heterozygous KRAS codon 12 or 13 mutations is detected. 3 In individual patients, these point mutations are frequently detected in both primary and metastatic lesions, 4, 5 consistent with the notion that KRAS mutations are acquired early during colorectal tumorigenesis.
Panitumumab is a fully human monoclonal antibody that targets the extracellular region of EGFR and effectively blocks ligand-dependent signaling downstream of the receptor. In the first-line 20050203 study, 6 the second-line 20050181 study, 7 and the monotherapy 20020408 study, 8, 9 panitumumab significantly improved progression-free survival (PFS) and response rate in patients with wild-type (wt) KRAS mCRC but not in their mutant KRAS mCRC counterparts. Collectively, mutant KRAS codon 12 and 13 alleles are established biomarkers for lack of response to anti-EGFR monoclonal antibodies in patients with mCRC. 6, 7, [9] [10] [11] However, recent retrospective analyses 12, 13 have suggested that patients whose tumors harbor a specific KRAS exon 2 mutation, a glycine (G; single-letter amino acid code) to aspartate (D) mutation at codon 13 (G13D), may derive clinical benefit from an anti-EGFR monoclonal antibody therapy in chemorefractory settings and in firstline combination therapy with irinotecan or oxaliplatin. In this analysis of 1,053 patients with mutant KRAS codon 12 or 13 alleles, we retrospectively examined the seven most common mutant KRAS codon 12 and 13 alleles for their prognostic and predictive impact on outcomes in patients with mCRC receiving panitumumab-containing therapy across three randomized phase III studies.
PATIENTS AND METHODS

Data Sets
Studies For all three phase III trials, key eligibility criteria included age Ն 18 years, metastatic adenocarcinoma of the colon or rectum, measurable disease, ECOG performance status of 0 to 2, no prior anti-EGFR therapy, and paraffinembedded tumor tissue available for central biomarker analyses. The KRAS status of patients' tumors was neither required nor assayed at study entry but was performed after all patients had been enrolled.
KRAS testing was conducted by a blinded central laboratory and determined by using the TheraScreen K-RAS Mutation Kit (Qiagen, Manchester, United Kingdom) that detects the seven most common mutations in KRAS codons 12 and 13 (KRAS G12A, G12C, G12D, G12R, G12S, G12V, and G13D). Individual KRAS allele testing was performed without knowledge of patient clinical outcomes. Descriptive statistics were provided for patient demographics and baseline characteristics in studies 20050203 and 20050181 but were not conducted in study 20020408 because of the relatively low number of patients with each mutant KRAS allele.
Statistical Analysis
The primary objective of this study was to examine the prognostic and predictive impact of the seven most common mutations in KRAS codons 12 and 13 on PFS, OS, and response rate in patients with mCRC who received panitumumab or control therapy. The analysis was conducted separately for each KRAS allele, for each study, and for all three studies combined. For prognostic analyses, comparisons were made between the outcomes of patients whose tumors harbored a specific KRAS mutation and the remaining patients whose tumors harbored any of the remaining six mutant KRAS alleles. Prognostic analyses were performed exclusively on patients who received control therapy (ie, non-panitumumab-containing). For analyses of the predictive impact of mutant KRAS alleles, relative treatment effects of panitumumab-containing and non-panitumumab-containing therapies were estimated among patients whose tumors harbored wt KRAS, any of the indicated mutant KRAS alleles (analyzed together as a group), or the specified individual mutant KRAS allele. Hazard ratios (HRs) and 95% CIs for PFS and OS were obtained by using the Cox proportional hazards model. A descriptive quantitative interaction test 14 was conducted to assess the relative treatment effect on PFS and OS between the specific mutant KRAS codon 12 or 13 allele and the other KRAS mutations. No adjustments were made for multiple testing. HRs were stratified by study for the pooled analysis. All statistical evaluations were performed with SAS software, version 11 (SAS Institute, Cary, NC). G12D  68  31  57  26  77  32  70  28  21  38  22  31  G12V  57  26  64  29  62  26  79  32  10  18  18  26  G13D  46  21  52  24  39  16  45  18  9  16  11  16  G12C  16  7  19  9  26  11  19  8  6  11  6  9  G12A  21  10  13  6  17  7  17  7  6  11  5  7  G12S  13  6  14  6  12  5  13  5  4  7  6  9  G12R  0  0  1  Ͻ 1  5  2  4  2  0  0  2  3 Abbreviations: BSC, best supportive care; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX4, infusional fluorouracil, leucovorin, and oxaliplatin; mCRC, metastatic colorectal cancer; Pmab, panitumumab.
RESULTS
Patients
The results are consistent with published mCRC KRAS mutation analysis [15] [16] [17] [18] and are comparable to the more than 9,000 primary colon and rectum adenocarcinoma cases in the public Catalogue of Somatic Mutations in Cancer (COSMIC) mutation database. 19 Together, KRAS G12D, G12V, and G13D comprised more than 70% of all mutant KRAS codon 12 and 13 alleles in each of the three studies. KRAS G12R was detected in less than 2% of mutant KRAS tumors and was not analyzed further.
Baseline Fig A2, online only) with the percentage of white patients, ECOG performance status, primary tumor site, incidence of liver plus other metastatic sites, prior surgery, and intensity of study therapy being similar across KRAS allelic subgroups and by treatment arm.
Prognostic Impact of KRAS Alleles
To evaluate the prognostic impact of KRAS codon 12 and 13 mutations, HRs with corresponding 95% CIs were plotted for the nonpanitumumab-containing control arms of the first-line (20050203), second-line (20050181), and monotherapy (20020408) studies (Fig 1) . HRs for patients whose tumors harbored each of the individual mutant alleles were ordered by allele frequency and were compared with the other mutant KRAS codon 12 and 13 alleles combined.
The 95% CIs for the calculated HRs did not cross unity for mutant KRAS allele G12C (HR, 2.06; 95% CI, 1.16 to 3.65), which appeared as a negativeprognosticfactorforPFSbutnotforOSinstudy20050203.None of the mutant KRAS alleles in study 20050181 were associated with a prognostic impact. In study 20020408, the 95% CIs for the calculated HRs did not cross unity for alleles KRAS G12C (HR, 2.47; 95% CI, 1.04 to 5.90) and KRAS G12A (HR, 5.30; 95% CI, 1.96 to 14.34), which both appeared as negative prognostic factors for OS but not for PFS. Taken together, no single mutant KRAS allele was a consistent negative or positive prognostic factor for both PFS and OS or across lines of mCRC therapy.
Predictive Impact of KRAS Alleles on Panitumumab Efficacy
The predictive effect of mutant KRAS codon 12 and 13 alleles on PFS and OS was also evaluated in all three phase III panitumumab studies (Fig 2) . HRs with 95% CIs were plotted for patients whose
Favors indicated mutation Favors other mutations PFS Hazard Ratio (positive/others) tumors harbored either wt KRAS or the indicated individual mutant KRAS alleles and were compared with the entire collection of mutant KRAS alleles. KRAS G13D was the only allele for which the 95% CIs for the calculated HRs did not cross unity, and it appeared as a negative predictive factor for both PFS (HR, 1.60; 95% CI, 1.05 to 2.46) and OS (HR, 2.47; 95% CI, 1.51 to 4.03) in the panitumumab-containing arm of the first-line 20050203 study. However, when a quantitative interaction test was conducted (Table 2) , KRAS G13D was significantly associated only with a negative impact on OS (P ϭ .0018) but not PFS (P ϭ .1609). A borderline statistically significant positive impact on OS in study 20050203 was observed by interaction testing for KRAS G12V (P ϭ .0369), but the 95% CIs for the calculated OS HR crossed unity (Fig 2) . Taken together, across three studies, none of the individual mutant KRAS alleles were consistently associated with panitumumab treatment effects on PFS or OS outcomes. However, consistent with previous reports, 6,7,9 mutant KRAS alleles as a collective group were a negative predictive factor for both PFS and OS in panitumumab-containing therapies.
Response rates with 95% CIs were plotted for patients whose tumors harbored wt KRAS, any mutant KRAS codon 12 and 13 allele, or any indicated individual mutant KRAS allele (Appendix Fig A3,  online only) . In studies 20050203 and 20050181, objective responses for patients with mutant KRAS mCRC included only partial responses, and no complete responses were observed.
6,7 Response rates were similar across all mutant KRAS allele subgroups within each of the first-and second-line mCRC trials; 95% CIs for response rates of all individual mutant KRAS allele subgroups overlapped with each other, indicating no predictive effects of individual mutant KRAS codon 12 and 13 alleles on response rates. In study 20020408, no patient whose tumor harbored a mutant KRAS codon 12 or 13 allele responded to panitumumab therapy. As a collective group, mutant KRAS alleles were a negative predictive factor for response rate in the panitumumab-containing arms of all three trials.
Pooled Analysis of the Predictive Effect on PFS and OS by KRAS Alleles Across Panitumumab Studies
Pooled analysis of the three phase III trials was performed to increase sample size and to detect any significant trends that were not detectable in the individual studies. The analysis used individual patient-level data stratified by study. HRs and 95% CIs for PFS and OS 
OS Hazard Ratio (panitumumab/control) KRAS Allele (Fig 3) . Only a single mutant KRAS allele, G12A, emerged as a predictive factor and was associated with a negative panitumumab treatment effect on OS but not on PFS. The earlier noted impacts of mutant KRAS G12V and KRAS G13D alleles on patient outcomes were no longer observed in the pooled analysis.
DISCUSSION
Preclinical studies have suggested that individual KRAS codon 12 or 13 alleles have displayed quantitative and/or qualitative differences in transforming capacity and other biologic phenotypes. Specifically, KRAS codon 12 mutations have displayed greater in vitro transforming ability when compared with KRAS codon 13 mutations, [20] [21] [22] and individual mutant KRAS codon 12 alleles have had a differential impact on cellular transformation. 23 Furthermore, the signaling networks activated downstream of individual mutant KRAS alleles have varied significantly. 22, 23 Despite these intrinsic biologic differences observed in defined experimental systems, the differential prognostic or predictive impact of individual mutant KRAS codon 12 or 13 alleles in a genetically complex and heterogeneous disease such as mCRC have remained untested by a systematic approach.
This study is the largest retrospective analysis evaluating the seven most common mutations in KRAS codons 12 and 13 for prognostic and predictive impact in patients with mCRC receiving an anti-EGFR therapy. Enrollment was completed in trials 20050203, 20050181, and 20020408 before KRAS was established as a predictive marker for outcomes in patients with mCRC. KRAS allele status was ascertained in more than 90% of the patients in each of the three phase III trials. A total of 1,053 patients were included in this analysis from these three open-label, multicenter, randomized, controlled phase III trials. The frequency and distribution of mutant KRAS codon 12 and 13 alleles were conserved across the trials, equally balanced between the treatment and control arms, and consistent with public domain data and prior publications. [15] [16] [17] [18] [19] Baseline demographics and clinical features were also balanced by treatment arm and comparable between all mutant KRAS allelic subgroups in trials 20050203 and 20050181.
Analysis of mutant KRAS codon 12 and 13 alleles on prognosis in the control arms of the three phase III trials suggested a trend toward a negative prognostic factor for KRAS G12C on PFS for patients receiving FOLFOX4 and on OS for patients receiving BSC. A trend as a negative prognostic factor was also observed for KRAS G12A on OS for patients receiving BSC. However, no single mutant KRAS allele was a consistent prognostic factor on both PFS and OS or across lines of mCRC therapy.
The prognostic significance of KRAS mutations has been assessed in a multitude of studies, with conflicting results. 24 Several studies have suggested that KRAS mutations are a negative prognostic indicator in CRC. 25 When considering the five largest studies, a prognostic impact was reported by four of these studies. 26 The RASCAL II metaanalysis indicated that KRAS G12V in Duke's C CRC patients was associated with a significant reduction in disease-free survival and OS.
17,27 Samowitz et al 28 performed the first population-based study on KRAS mutations in CRC, and results suggested that mutations in KRAS codon 13 were associated with poor OS. In addition, De Roock et al 12 recently reported that KRAS G13D mCRC tumors had worse OS compared with wt KRAS tumors and compared with tumors bearing other KRAS mutations, although significance was lost in multivariate analysis. 12 In contrast, a large number of reported studies (reviewed in Klump et al 26 ) have found no association of KRAS gene mutations with survival, either in isolation or in combination with other tumor suppressor genes. Interpretation of the various studies published on the prognostic role of KRAS in mCRC may be challenging because of the different KRAS mutations investigated and variations in data collection, staging techniques, and mutant KRAS detection methodologies. In patients with mCRC treated with an anti-EGFR monoclonal therapy, it has been suggested that KRAS mutations are unlikely to be prognostic (independent of any specific treatment) and are likely predictive (attributable to treatment). 29 In the analysis reported here, there was no consistent evidence that any individual mutant KRAS allele, compared with the remaining mutant KRAS alleles or the entire mutant KRAS group, had a differential impact on response rate, PFS, or OS. Only in the first-line FOLFOX4 treatment setting of study 20050203 were statistically significant differences observed for individual mutant KRAS alleles: KRAS G12V was favorably and KRAS G13D was unfavorably associated with panitumumab treatment effects on OS but not on PFS or response rate. Because associations with OS were observed only in the FOLFOX4 treatment setting and because other KRAS mutations have been associated with platinum sensitivity, 30 it is possible that selected mutant KRAS alleles may have a differential impact on patient outcomes in the specific context of coadministration with oxaliplatincontaining chemotherapy.
High KRAS ascertainment rates and consistent KRAS testing methodology permitted the pooling of data from all three phase III trials to potentially identify predictive trends across three lines of therapy that may not have been observed from analysis of any single trial. Pooled analyses indicated that no individual mutant KRAS codon 12 and 13 allele was associated with outcomes for both PFS and OS, relative to other KRAS mutations. A trend was observed for KRAS G12A, which was associated with a negative panitumumab predictive effect only on OS. KRAS alleles G12V and G13D were no longer associated with outcomes in the pooled analysis, suggesting there were no predictive trends across lines of therapy.
These results are in contrast with reported cetuximab data, 12, 13 which have suggested patients with KRAS G13D responded to an anti-EGFR monoclonal antibody therapy. However, this improved survival in patients with KRAS G13D was not significant in the cetuximab monotherapy arm, and therefore the confounding effect of the chemotherapy backbone cannot be excluded. 12 In addition, a recent retrospective analysis of 110 patients treated with cetuximab 31 reported that patients whose tumor harbored a KRAS G13D allele did not benefit from cetuximab treatment (n ϭ 12) and had a trend toward lower OS compared with patients whose tumors harbored either wt KRAS or one of the other KRAS mutations. Although panitumumab and cetuximab recognize similar epitopes, 32 they are of different antibody isotypes and may have different abilities to bind to EGFR mutations. 33 It is unclear whether these or other characteristics may have contributed to the conflicting results reported between these antibodies.
The cetuximab studies 12, 13, 31 and the analysis reported here were limited by their retrospective nature, they used subset analysis, and were subject to chance observations. None of the studies made adjustments for multiple testing. Other possible limitations were the low frequency and low number of patients in the specific mutant KRAS allelic subgroups, such as in the De Roock et al study 12 which had a total of 32 patients in the KRAS G13D subgroup in pooled analyses of patients in cetuximab monotherapy (n ϭ 10) and cetuximab plus chemotherapy studies (n ϭ 22).
On the basis of all of the available data and consistent with current clinical treatment guidelines, we suggest that patients with mCRC tumors that harbor any of the most common mutant KRAS codon 12 or 13 alleles are unlikely to benefit from panitumumab therapy. Therefore, only mCRC patients with wt KRAS tumors should be treated with panitumumab therapy.
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